Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
PARIS, FRANCE / ACCESSWIRE / July 12, 2021 / Pharnext SA (FR0011191287 – ALPHA) (the…